HOXA9 methylation is not associated with survival in Brazilian patients with lung adenocarcinoma.

IF 4.8 2区医学 Q1 GENETICS & HEREDITY

Clinical Epigenetics Pub Date : 2025-02-17 DOI:10.1186/s13148-025-01831-1

Anna Luiza Silva Almeida Vicente, Fabiana Aparecida de Souza Santos, Welinton Yoshio Hirai, Delphine Lissa, Rodrigo de Oliveira Cavagna, Aline Larissa Virginio da Silva, Mariana Bisarro Dos Reis, Eduardo Caetano Albino da Silva, Flávio Augusto Ferreira da Silva, Josiane Dias Mourão, Pedro De Marchi, Ana Carolina de Carvalho, Letícia Ferro Leal, Rui Manuel Reis

{"title":"HOXA9 methylation is not associated with survival in Brazilian patients with lung adenocarcinoma.","authors":"Anna Luiza Silva Almeida Vicente, Fabiana Aparecida de Souza Santos, Welinton Yoshio Hirai, Delphine Lissa, Rodrigo de Oliveira Cavagna, Aline Larissa Virginio da Silva, Mariana Bisarro Dos Reis, Eduardo Caetano Albino da Silva, Flávio Augusto Ferreira da Silva, Josiane Dias Mourão, Pedro De Marchi, Ana Carolina de Carvalho, Letícia Ferro Leal, Rui Manuel Reis","doi":"10.1186/s13148-025-01831-1","DOIUrl":null,"url":null,"abstract":"<p><p>Homeobox A9 promoter methylation (HOXA9) has been reported as a biomarker for early lung adenocarcinoma patients' prognosis. We aim to evaluate its prognostic value, regardless of disease stage. Using droplet digital PCR, we measured HOXA9 methylation in a cohort comprising 161 Brazilian patients. Low HOXA9 methylation was associated with higher cancer-specific survival but showed no significance after adjustment for clinical covariates. While low HOXA9 methylation was associated with earlier stages, no survival association was observed in this subset of patients. Overall, HOXA9 promoter methylation is not an independent prognostic biomarker of cancer-specific survival in Brazilian lung adenocarcinomas patients.</p>","PeriodicalId":10366,"journal":{"name":"Clinical Epigenetics","volume":"17 1","pages":"25"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834317/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epigenetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13148-025-01831-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Homeobox A9 promoter methylation (HOXA9) has been reported as a biomarker for early lung adenocarcinoma patients' prognosis. We aim to evaluate its prognostic value, regardless of disease stage. Using droplet digital PCR, we measured HOXA9 methylation in a cohort comprising 161 Brazilian patients. Low HOXA9 methylation was associated with higher cancer-specific survival but showed no significance after adjustment for clinical covariates. While low HOXA9 methylation was associated with earlier stages, no survival association was observed in this subset of patients. Overall, HOXA9 promoter methylation is not an independent prognostic biomarker of cancer-specific survival in Brazilian lung adenocarcinomas patients.

查看原文本刊更多论文

HOXA9甲基化与巴西肺腺癌患者的生存无关。

同源盒A9启动子甲基化（HOXA9）已被报道为早期肺腺癌患者预后的生物标志物。我们的目的是评估其预后价值，而不考虑疾病分期。使用液滴数字PCR，我们测量了161名巴西患者的HOXA9甲基化。低HOXA9甲基化与较高的癌症特异性生存率相关，但在调整临床协变量后没有显示出显著性。虽然低HOXA9甲基化与早期阶段相关，但在这部分患者中未观察到生存相关。总的来说，HOXA9启动子甲基化并不是巴西肺腺癌患者癌症特异性生存的独立预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epigenetics ONCOLOGY-

自引率

5.30%

发文量

150

期刊介绍： Clinical Epigenetics, the official journal of the Clinical Epigenetics Society, is an open access, peer-reviewed journal that encompasses all aspects of epigenetic principles and mechanisms in relation to human disease, diagnosis and therapy. Clinical trials and research in disease model organisms are particularly welcome.